Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

ABSTRACT: Carbapenem-resistant organisms (CRO) are a major global public health threat. Enterobacterales hydrolyze almost all ?-lactams through carbapenemase production. Infections caused by CRO are challenging to treat due to the limited number of antimicrobial options. This leads to significant morbidity and mortality. Over the last few years, several new antibiotics effective against CRO have been approved. Some of them (e.g., plazomicin or imipenem-cilastatin-relebactam) are currently approved for use only by adults; others (e.g., ceftazidime-avibactam) have recently been approved for use by children. Recommendations for antibiotic therapy of CRO infections in pediatric patients are based on evidence mainly from adult studies. The availability of pediatric pharmacokinetic and safety data is the cornerstone to broaden the use of proposed agents in adults to the pediatric population. This article provides a comprehensive review of the current knowledge regarding infections caused by CRO with a focus on children, which includes epidemiology, risk factors, outcomes, and antimicrobial therapy management, with particular attention being given to new antibiotics.

SUBMITTER: Aguilera-Alonso D 

PROVIDER: S-EPMC7038253 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature